



ASX RELEASE

12 January 2009

## Hc BERLIN PHARMA AG IN EUROPEAN ALLIANCE AGAINST MALARIA

Eastland medical Systems Ltd (EMS) provides the following announcement from Hc Berlin Pharma AG, Eastland's contracted manufacturing partner for their **ArTiMist™** malaria treatment. Eastland is a significant investor in Hc Berlin Pharma AG.

### ***Hc Berlin Pharma AG takes part in the meeting of the European alliance against Malaria.***

*Berlin, 19th of December, 2008 - The HC Berlin Pharma AG has taken part on the 17th of December, 2008 in Berlin in a meeting of the European alliance against malaria on which the world malaria report of the WHO 2008 was presented as well as the Global Malaria Action Plan of the Roll Back Malaria (RBM) partnership.*

*In the "European Alliance against Malaria" eleven prestigious European Non-Government Organisations have united to speed up the international efforts in the fight against Malaria with all emphasis. Their aim is to win decision makers and representatives of the civil society as a comrade-in-arms for a powerful and determined action against Malaria*

*The Alliance has eleven members, two from Germany – the German Red Cross (German Red Cross) and the German Foundation World Population (DSW). Patronage is with Federal Development Minister Heidemarie Wiecek-Zeul.*

*The Action Plan of Roll Back Malaria partnership is a guideline for the international developing community and gives hope for a stringent and co-ordinate answer of governments, the private sector and civil-social organisations to this global challenge. Based on data of the World Health Organization the action plan indicates strategies and action recommendations how malaria can be controlled in future and be fought permanently.*



*From the left to the right: WHO Dr. Richard Cibulski, Chief Epidemiologist; Karin Kortmann, Parliamentary Secretary of State with the Federal Minister for economic cooperation and development; Renate Bähr, Manager German Foundation world population (DSW); Prof. Dr. Awa Marie Coll-Seck, Manager, Roll Back Malaria Partnership (RBM); Christina Schrader, Manager, Strategic Global Initiatives, Global Fond to fight AIDS, Tuberculosis and Malaria*

*Hc Berlin Pharma was represented by the CEO Mr. Ottmar Geiger and the Chairman of the Supervisory Board Mr. R. Schötteldreier who used the opportunity to talk about a new Malaria Treatment for children called **ArTiMist™**.*

For personal use only



*The interest of the participants in this forthcoming sublingual spray which was mainly developed for the treatment of complicated and uncomplicated malaria in children was enormous. The information on the expected availability of the treatment within the next year was received very positive by the participants.*

“To date there has been significant global interest in the eradication of malaria from government and non-government agencies around the world,” said Eastland’s CEO Dermot Patterson. “It is pleasing to see that, through our contract manufacturing partner Hc Berlin Pharma AG, our anti-malarial sublingual spray treatment **ArTiMist™** is gaining the notice of European Alliance against Malaria.”

Eastland has successfully completed Phase 1 Single and Multi dose clinical trials for **ArTiMist™** in Malaysia in November 2007 and South Africa in February 2008 with positive results indicating it is safe to use, showing no adverse effects in any of the trial subjects. Further clinical trials are due to be commenced within the coming weeks. “A successful trial of the **ArTiMist™** treatment over the next few weeks will pave the way for Eastland to fast-track the treatment to commercialisation and enter the market,” said Mr. Patterson.

For further information:

Dermot Patterson  
Chief Executive Officer  
Eastland Medical Systems Ltd  
t: +61 (0) 8 9436 9500  
f: +61 (0) 8 9436 9505  
m: +61 (0) 417 915 511  
[www.eastlandmedical.com.au](http://www.eastlandmedical.com.au)

**ASX Announcement No 367 of 2 pages 12 January 2009**

For personal use only